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Glucagon-like peptide 1 (GLP-1) mimetics are effective
drugs for treatment of type 2 diabetes, and there is
consequently extensive interest in increasing endoge-
nous GLP-1 secretion and L-cell abundance. Here we
identify G-protein–coupled bile acid receptor 1 (GPBAR1)
as a selective regulator of intestinal L-cell differentiation.
Lithocholic acid and the synthetic GPBAR1 agonist, L3740,
selectively increased L-cell density in mouse and human
intestinal organoids and elevatedGLP-1 secretory capacity.
L3740 induced expression of Gcg and transcription factors
Ngn3 andNeuroD1. L3740 also increased the L-cell number
and GLP-1 levels and improved glucose tolerance in vivo.
Further mechanistic examination revealed that the effect of
L3740 on L cells required intact GLP-1 receptor and sero-
tonin 5-hydroxytryptamine receptor 4 (5-HT4) signaling.
Importantly, serotonin signaling through 5-HT4 mimicked
the effects of L3740, acting downstream of GLP-1. Thus,
GPBAR1agonists andother powerfulGLP-1 secretagogues
facilitate L-cell differentiation through a paracrine GLP-
1–dependent and serotonin-mediated mechanism.
Synthetic glucagon-like peptide 1 (GLP-1) analogs and
dipeptidyl peptidase 4 (DPP-4) inhibitors today constitute
effective components of type 2 diabetes treatment. Both
strategies potentiate the action of the GLP-1 system, leading
to beneficial effects on insulin and glucagon secretion, food
intake, and nutrient metabolism. Consequently, increasing
the number of intestinal endocrine L cells, the main source
of GLP-1, represents an attractive alternative strategy for
augmenting GLP-1 bioavailability (1–3).
Differentiation of L cells is a continuous process in the
intestine. Constantly renewing intestinal epithelium has
the capacity to expand the population of L cells if the
appropriate signals are present (4). In the crypts of the
intestine, stem cells expressing Lgr5 give rise to prolifer-
ating transit-amplifying cells. Each one of these cells can
become a secretory cell progenitor expressing a specific
lineage marker Math1 or an absorptive cell progenitor
labeled by Hes1 expression—a process controlled by Notch
signaling. Next, some of these secretory cell progenitors
start expressing Ngn3, which defines endocrine progeni-
tors (5). At the next stage, new transcription factors direct
the maturation toward a certain hormonal cell type (6),
where NeuroD1, Arx, Foxa 1, and Foxa 2 are associated with
differentiation into L cells (7–9). In addition to GLP-1, L
cells secrete other hormones important for metabolic
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regulation, such as cholecystokinin (CCK), neurotensin,
and peptide YY (PYY). Somatostatin (SST)-secreting cells
and serotonin (5-hydroxytryptamine [HT])-secreting cells,
which constitute most of the enteroendocrine cell popu-
lation, develop as mostly separate branches.
We previously showed that differentiation of L cells can
be pharmacologically increased in vitro and in vivo by
a Notch inhibitor (1) and Ras homolog family member
A-associated coiled-coil–containing protein kinases (ROCK)
inhibitor (3) through a general increase in the proportion of
secretory cells. The subsequent increase in L-cell number
resulted in amplified GLP-1 secretion, which augmented
insulin responses and restored glucose tolerance in a mouse
model of type 2 diabetes (1,3). However, the therapeutic
potential of Notch and ROCK inhibitors used to manipulate
L-cell differentiation is limited due to adverse effects during
long-term application of these drugs because their effects
are not selective to the L-cell lineage. On the other hand,
short-chain fatty acids (SCFAs), endogenous products of
intestinal microbiota metabolism, selectively enhance dif-
ferentiation and consequently the number of L cells (9,10).
SCFAs are also effective GLP-1 secretagogues (11), and thus,
we hypothesized that locally amplified GLP-1 secretion
drives L-cell differentiation. Among other natural GLP-1
secretagogues, secondary bile acids, synthesized by in-
testinal microflora from primary bile acids, are powerful
stimulants of GLP-1 release through activation of the G–
protein–coupled bile acid receptor 1 (GPBAR1) (12–14).
Lithocholic acid (LCA) has the highest affinity to GPBAR1
among secondary bile acids (13). In humans, plasma
concentrations of bile acids are at the low micromolar
range (15). Intracellularly, GPBAR1 activates the Gs signal-
ing pathway resulting in increased cAMP, which is partic-
ularly effective in stimulating release of GLP-1 (16) and
other coexpressed peptide hormones from the L cell, in-
cluding PYY and neurotensin (17). Therefore, synthetic
GPBAR1 agonists are promising drug candidates acting
locally in the intestine to enhance GLP-1 secretion (18).
In this study, the effect of GPBAR1 activation on L-cell
number, GLP-1 secretion, and gene expression of L-cell
lineage markers was tested in the small intestine organoid
platform. The observed positive effect of GPBAR1 ago-
nists on L-cell differentiation was dependent on GLP-1
signaling and, surprisingly, mimicked by downstream
serotonin signaling conceivably through paracrine stim-
ulation from neighboring enterochromaffin cells (19).
RESEARCH DESIGN AND METHODS
Animals
Nonfasted male GLU-Venus mice with transgenic expres-
sion of yellow fluorescent protein (YFP) in L cells (20),
GPBAR1 knockout (KO) mice (12), their wild-type litter-
mates, and GLP 1 receptor (GLP-1R) KO mice (21) bred on
C57BL/6J background were used for organoids studies at
the age of 6–8 months, and GLU-Venus female mice were
used for in vivo testing at the age of 3–4 months. Mice of
different age were used to reduce costs for mouse colony
maintenance. We did not expect a difference in the
mechanisms of intestinal cell differentiation in 3- to 8-month-
oldmice or significant differences betweenmales and females.
In our experience, organoids from 3- or 8-month-old males
and females show similar characteristics. In all experiments,
littermates from the same cage were used as controls.
C57BL/6 mice were purchased from Charles River. All
animal experiments were approved by the Danish Animal
Inspectorate (2018-15-0201-01424).
Human Intestinal Samples
Human jejunum fragments were obtained from Roux-
en-Y gastric bypass operations from four patients with
no anticancer treatment (Sydvestjysk Hospital, Esbjerg,
Denmark). All patients participated with informed con-
sent, with the research protocol approved by the National
Research Ethics Committee (H-18015120).
Mouse and Human Organoid Culture and Experiment
Design
Mice were sacrificed by cervical dislocation. Small-intestine
crypts were isolated from the ileum by EDTA incubation
(22) and seeded in Matrigel in advanced DMEM/F12 con-
taining 100 units/mL penicillin/streptomycin, 10 mmol/L
HEPES, 2 mmol/L GlutaMAX, supplements N2 and B27,
50 ng/mL murine epidermal growth factor (all from Life
Technologies), 1 mmol/L N-acetylcysteine (Sigma-Aldrich),
100 ng/mL murine Noggin, and 500 ng/mL murine
R-spondin-1 (PeproTech). For maintenance, organoids
were split every 4–6 days and cultured in 48-well plates. Test
compounds were added into the culture medium, and the
organoids were analyzed after 48 h. By the time of the
readout, most of the organoids had three to five crypts.
Duodenal organoids were generated and analyzed the same
way. Human organoid lines were generated and cultured as
previously described (23). The experiments were performed
after the first passage.
LCA (Sigma-Aldrich), L3740 (Merck-TGR5-A) (17), tro-
pisetron, RS-39604, BIMU 8 (all from Tocris), GPR40
agonist AM-1638 (24), and GPR119 agonist AR53 (AR231453)
(16,24) were first dissolved in DMSO as 1 mmol/L stock, and
diluted with the culture medium to 10, 20, or 50 mmol/L
for LCA and 1 mmol/L for other compounds. DMSO (0.01%)
was added to control wells. After 48 h, the organoids were
collected for quantitative (q)PCR analysis or fixed in 4%
paraformaldehyde for GLP-1 immunostaining (for human,
GPBAR1 KO, wild-type, and GLP-1R KO mouse organoids)
(10) and microscopy analysis. The experiment was performed
three to six times in duplicates using organoids from six
mice. The L-cell percentage in organoids was assessed in
whole mount preparation from a three-dimensional stack
of 10-mm-thick digital sections, each containing three
to eight organoids, acquired on a Zeiss confocal micro-
scope (LSM 780) at 320 magnification using Zen Soft-
ware. Label-positive cells from each image were manually
counted and expressed as the percentage of cells calcu-
lated from nuclear labeling with DAPI, analyzed with
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ImageJ software. The number of measurements is pre-
sented in Figure legends.
GLP-1 Secretion Measurements
Organoids cultured in 96-well plates for 48 h were washed
three times in Advanced DMEM/F12 with HEPES and
L-glutamine. Medium with stimulants (L3740, LCA, or BIMU
8) and control medium (without stimuli) was added to the
wells with five replicates for each condition (unless other-
wise indicated) and slowly shaken on an orbital shaker
after addition of the medium and before the collection.
After 2 h at 37°C, the medium was collected and assayed
for GLP-1 content using the GLP-1 V-Plex Meso Scale
Discovery kit (Meso Scale Diagnostics). For glucose stim-
ulation, the organoids were washed and preincubated with
DMEM supplemented with 2% FBS containing no glucose
and glutamine for 1 h. Then DMEM containing 18 mmol/L
glucose and 2 mmol/L L-glutamine or DMEM with no
stimulants (control) was added. The experiment was
performed three to four times. The values were nor-
malized to the DNA content in the wells measured with
a DNA quantification kit (Sigma-Aldrich).
qPCR
Total RNA was extracted from organoids using the mini
RNA extraction kit (Qiagen). cDNA was synthesized using
the SuperScript III kit (Invitrogen, Thermo Fisher Scien-
tific, Waltham, MA). Real-time qPCR was performed on
a real-time PCR System (Bio-Rad) using SYBR green assays.
We used beta-2-microglobulin (B2M) as the endogenous
control gene (10). Mouse and human primer sequences
were described previously (3,10) and for Gpbar1, 5Htr3a,
5Htr3b, and 5Htr4 are presented in Supplementary Table
1. Each gene expression was tested in two to four organoid
lines from different mice generating two to four templates
from each line from different passages (biological re-
plicates, n) in independent experiments. The individual
measurements were averaged from duplicated qPCR wells
(technical replicates).
In-Feed GPBAR1 Agonist Treatment
Two groups of Glu-Venus mice were fed regular feed ground
into powder for 4 days before the experiment. The body
weight was monitored for potential weight losses due to the
feed change. Mice with stable body weight were randomized
so that one group received L3740-containing feed for
3 days, and the other continued with the same powder
feed (control). Assuming that mice consumed at least
2.8 g of feed during 24 h (25), the mice received;60 mg/kg
body wt of the compound per day (0.64 mg L3740 per 1 g
mouse feed). The mice were fasted for 5 h before an oral
glucose tolerance test. Glucose (2 g/kg body wt) was given
as an oral gavage, and blood samples were taken before
and 15, 30, 60, and 120 min after the bolus. For plasma
GLP-1 measurements, blood (;50 mL) was collected from
the retro-orbital sinus from a separate cohort of L3740-
treated and control mice before (0 min) and 10 min after
the glucose bolus. The total GLP-1 Meso Scale Discovery
assay (cat. no. K150JVC-4) was used for determination of
plasma GLP-1 concentrations. Mice were euthanized, and
fragments of ileum 2 cm from cecum were collected and
fixed in 4% paraformaldehyde. The percentage of YFP-
positive cells was calculated in six to eight transverse
cryosections per mouse as described above. Blood glucose
was measured with a Contour-Next Glucometer (Bayer).
Area under the curve with baseline subtraction was
calculated for glucose dynamics using GraphPad Prism
8 software.
In Situ Hybridization
Adult C57BL/6 male mice were euthanized by cervical
dislocation, and fragments of intestine were excised, rinsed,
and fixated by flushing with Bouin fixative (50% ethanol
and 5% acetic acid in deuterium H2O). The intestines were
cut open and rolled onto a toothpick to create so-called
Swiss rolls. “Rolls” were fixated 24 h in 4% paraformalde-
hyde and subsequently embedded in paraffin. In situ hybrid-
ization was performed on 5-mm sections using RNAscope
Multiplex Fluorescent Assay (ACDBio) with the probes for
Htr4 (Mm-Htr4, #408241), Htr3a (Mm-Htr3a, #411141),
Lgr5 (Mm-LGR5-C3, #312171-C3), Math1 (Mm-Atoh1-C3,
#408791-C3), CD133 (Mm-Prom1-C3, #412221-C3), and
Ngn3 (Mm-Neurog3-C2, #422401-C2) following manu-
facturer’s instruction. Htr4, CD133, and Ngn3 were applied
as a triple labeling. Images of staining were acquired on LSM
780 using Zen Software.
Statistics
Quantitative results are presented as mean values with
SEM. Comparison of two groups was done using the non-
paired two-tailed Student t test, assuming normality of data.
qPCR data were analyzed using the Wilcoxon matched-pairs
signed rank test for data from different organoid lines. P
values of,0.05 were considered significant. Data involving
more than two groups were assessed by ANOVA with
Bonferroni post hoc test using GraphPad Prism 8 software.
Data and Resource Availability
The data sets generated during the current study are
available from the corresponding author on reasonable
request.
RESULTS
Activation of GPBAR1 Increases L-Cell Number in
Intestinal Organoids
To investigate whether GPBAR1 activation could increase
L-cell number, we applied LCA to organoids generated
from GLU-Venus mouse ileum crypts, where L cells are
labeled by transgenic YFP expression (20). The addition
of 10 mmol/L LCA to the culture medium for 48 h
increased the L-cell number twofold (Fig. 1A and B).
Increasing the LCA concentration did not increase L-cell
number further (Supplementary Fig. 1A and B); however,
20 and 50 mmol/L LCA impaired crypt formation in
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organoids, indicating toxicity, which was not observed
with application of 10 mmol/L LCA (Supplementary
Fig. 1A). To avoid potential nonspecific effects, we used
L3740, a potent, synthetic, nondetergent GPBAR1 agonist
(17) (Supplementary Fig. 1C). Incubation with 1 mmol/L
L3740 increased the number of L cells by 2.5-fold within
48 h (Fig. 1C and D), while maintaining normal morphology
of the organoids (data not shown). Immunostaining for
GLP-1 confirmed that YFP-positive cells produced GLP-1
(Supplementary Fig. 1D). L cells weremostly localized to the
crypt domains in the control and L3740-treated groups. We
also tested the effect of L3740 on L-cell numbers in
duodenal organoids and found a 1.7-fold increase in the
L-cell percentage in the treated group compared with the
control group (Supplementary Fig. 1E).
Next, we tested GLP-1 secretion from GPBAR1-treated
organoids in response to a combination of natural stimu-
lants of GLP-1 release—glucose and L-glutamine—and
observed a 1.8-fold increase in the secretory capacity of
the cultures compared with the control (Fig. 1E), which is
in agreement with the observed increase in L-cell number.
Real-time qPCR analysis of specific cell markers was
used as an indirect measure of representation of different
cell types. We found increased expression of Gcg and Cck
transcripts in L3740-treated organoids but not of other
L-cell hormones such as Pyy and Nts (Fig. 1F). We tested
the expression of Tph1, a marker of serotonin-secreting
enterochromaffin cells, and found no difference between
the control and treated group. Because the Tph1 gene
encodes a key enzyme for serotonin synthesis and not the
final product, we also determined the enterochromaffin
cell representation and found no changes after the treat-
ment with L3740 (Supplementary Fig. 1F). Levels of mRNA
transcripts encoding the transcription factors NeuroD1 and
Ngn3 associated with L-cell endocrine specification was
also elevated, whereas expression of Arx, Foxa1, and Foxa2
remained unchanged (Fig. 1G). Expression of secretory cell
progenitor markers Math1 and Dll1 did not change, in-
dicating that the increase in L-cell number was modulated
after the Notch-mediated secretory cell specification (26).
Accordingly, the expression ofHes-1, amarker of progenitor
of nonsecretory absorptive cells, enterocytes, was the same
in control and L3740 groups. No changes in the expression
levels of I-fabp and Itf (enterocyte and goblet cell markers,
respectively) were observed, and the expression of Lyz1,
a Paneth cell marker, was slightly reduced (Fig. 1G). The
expression of Lgr5, a stem cell marker, was unchanged
(Fig. 1G).
To directly test whether GPBAR1 is required for bile
acid-induced L-cell differentiation, we generated organoids
from GPBAR1 KO mice and their wild-type littermates.
Exposure to L3740 did not affect the number of L cells
(Fig. 1H) or the expression of Gcg, Nd1, and Ngn3 (Fig. 1I)
in the absence of functional GPBAR1 signaling. Consistent
with these findings, L3740 and LCA did not induce GLP-
1 secretion from organoids lacking GPBAR1 (Fig. 1J).
Thus, LCA and L3740 both selectively induced L-cell
differentiation through mechanisms requiring functional
GPBAR1 signaling.
L3740 Increases L-Cell Numbers In Vivo
To investigate whether GPBAR1 stimulation can amplify
L-cell numbers in vivo, L3740 was administered o GLU-
Venus mice for 3 days in their feed. L3740-treated mice
showed a modest increase in glucose tolerance after an oral
glucose challenge (Fig. 2A and B) and elevated basal GLP-1
plasma levels (0 min) and 10 min after the gavage (Fig. 2C).
Body weight in the control and treated group before and
after the treatment was the same (Supplementary Fig. 1G).
There was no difference in feed intake between the groups
(2.6 6 0.1 vs. 2.7 6 0.1 g/mouse/day in control and
treated groups, respectively; NS). L-cell number in the
distal ileum was increased (Fig. 2D and E) and accompa-
nied by elevated expression of Gcg and Ngn3 compared
with controls (Fig. 2F). This indicates that the GPBAR1
agonist L3740 stimulates formation of new endocrine-
committed intestinal cells in vivo in mice.
GPBAR1 Stimulation Increases L-Cell Abundance in
Human Organoids
We next investigated the effect of GPBAR1 activation in
human intestinal epithelium. Human ileal organoids were
treated with 1 mmol/L L3740 for 48 h. Human organoid
culture requires the addition of Wnt3A and mitogen-
activated protein kinase inhibitors, which interfere with
normal cell differentiation, and the percentage of mature
cells in human organoids consequently is much lower
than in an intact intestine or in mouse organoids (23). In
mouse organoids, L cells were usually found in crypt
domains, whereas in human organoids, we did not ob-
serve a clear pattern for L-cell location (Fig. 3B). GPBAR1
stimulation induced a 1.6-fold increase in the L-cell
number compared with control cells (i.e., similar to what
was observed in the murine organoids) (Fig. 3A). Only
48% of vehicle-stimulated organoids contained L cells,
and most of those had only one or two L cells regardless of
the organoid size (Fig. 3B). After L3740 treatment, L cells
were observed in 71% of organoids (Fig. 3C). Considering
the irregular scattering of L cells, we compared the fre-
quency distribution of L cells in the organoid population. A
shift toward more cells per organoid was detected in the
L3740-treated group (Fig. 3C). The expression of GCG was
increased in the L3740-treated group as well as expression
of NEUROD1, but we did not detect changes in NGN3
expression, probably because the overall expression of
NGN3 was surprisingly low in the human organoids (Fig.
3D). These data indicate that L3740 stimulates L-cell
development also in human intestinal epithelium.
GPBAR1 Induction of L-Cell Differentiation Requires
Intact GLP-1 Signaling
We hypothesized that activation of GPBAR1 promotes
L-cell differentiation by chronically increasing secretion
of GLP-1. To test this, the effect of L3740 was probed in
diabetes.diabetesjournals.org Lund and Associates 617
Figure 1—Activation of GPBAR1 by the bile acid LCA and a synthetic agonist increases L-cell number in organoids. A: Representative
images of control and organoids treated with 10 mmol/L LCA. L cells are labeled by Gcg-YFP expression in this and following images unless
otherwise indicated. Nuclei labeled by DAPI. Scale bars, 50 mm. B: L-cell numbers in control (Ctrl) organoids (n5 70) and organoids treated
with LCA (n5 78). In this and following figures, the data are mean6 SEM (unless otherwise indicated). C: Representative images of control
and L3740-treated organoids. Scale bars, 50 mm. D: L-cell numbers in control (n 5 38) and L3740-treated organoids (n 5 30). E: GLP-1
secretion from L3740-treated organoids stimulated by 18 mmol/L glucose and 2 mmol/L L-glutamine. Data from three experiments were
performed with five replicas. F: Gene expression of intestinal hormones in L3740-treated organoids (n 5 4–10 in each series). G: Gene
expression of intestinal cell type markers and transcription factors directing L-cell development. Lgr5 and CD133, proliferating cells; ITF,
goblet cells; Lyz1, Paneth cells; I-Fabp, enterocytes; Ngn3, NeuroD1, Arx, and Foxa1/2, L-cell transcription factors (n5 4–10 experiments in
each series). H: L-cell numbers, identified by immunostaining, in control and GPBAR1 KO and wild-type (WT) mouse organoids after 48-h
treatment with L3740 (n 5 21–25). I: Expression of L-cell differentiation markers in control and L3740-treated GPBAR1 KO organoids (n 5
3 for each series). J: GLP-1 release in response to LCA and L3740 in GPBAR1 KO organoids (n 5 5 for each series). *P , 0.05, **P , 0.01,
***P , 0.001.
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intestinal organoids from GLP-1R KO mice (21). The
increase in L-cell number determined by immunostaining
was completely eliminated in the absence of functional
GLP-1R signaling (Fig. 4A). This indicates that the effect
of GPBAR1 activation requires the endogenous GLP-1R
and that L-cell number is regulated by a positive feed
forward mechanism.
In an attempt to maximize the proposed effect of GLP-
1R activation, we used 100 mmol/L liraglutide, a synthetic
GLP-1 analog, in the organoid culture medium and assessed
the L-cell number. Liraglutide increased the number of L
cells (Supplementary Fig. 2A), but interpreting this effect is
difficult because the peptide also had a pronounced stim-
ulatory effect on organoid growth (Supplementary Fig. 2B).
GLP-1 Secretagogues Induce L-Cell Differentiation
Through a Paracrine Cross Talk With Serotonin
Signaling
In the intestinal epithelium, the GLP-1R is almost
exclusively and highly expressed by the large population
of enterochromaffin cells producing serotonin, or 5-
hydroxytryptamine (5-HT) (19). Thus, we hypothesized
that differentiation of L cells could be mediated through
serotonin release. We stimulated L-cell differentiation in
mouse organoids with L3740 in the presence of two
different serotonin receptor inhibitors—tropisetron,
a prototype rather broad-spectrum serotonin antago-
nist blocking 5-HT receptor 3 (5-HTR3) and 5-HT re-
ceptor 4 (5-HTR4) (26), and 5-HTR4 blocker RS-39604.
Both drugs abolished L3740-induced L-cell differentia-
tion (Fig. 4B). In situ hybridization demonstrated that
the Htr4 is expressed in most epithelial cells of the small
intestinal crypts (Fig. 4C), and Htr3, as expected (27,28), is
expressed mainly in submucosal ganglia (Fig. 4C). In view of
these facts and because 5-HTR4 inhibition was sufficient to
inhibit the effect of L3740, we focused on the 5-HT4
receptor. Correspondingly, we found that L3740 treatment
increased the expression of Ht4r in the organoids (Fig. 4D).
To determine which differentiating cells in the crypt express
Htr4, we performed in situ hybridization costaining for
Htr4 and stem cell marker Lgr5, transit-amplifying cell
marker CD133, secretory progenitor marker Math1, and
endocrine progenitor marker Ngn3. We found that Htr4
was present in all these cell types (Fig. 4E). This is in
accordance with the capacity of these cells to differentiate
into L cells, which supports our discovery of a role for
serotonin in regulating the number of L cells.
Next, we incubated organoids with the 5-HTR4 agonist
BIMU 8 alone and in combination with L3740. BIMU
8 produced a similar increase in the number of L cells as
L3740, and combination of the two did not result in an
additive or synergistic effect (Fig. 4F). Importantly, BIMU
8 had no acute effect on GLP-1 release (Supplementary Fig.
2C). When tested in GLP-1R KO mouse organoids and
GPBAR1 KO mouse organoids, BIMU 8 still increased the
number of L cells (Fig. 4G and H), further supporting that
the increase in L-cell numbers by L3740 was an indirect
effect mediated by activation of serotonin receptors.
Based on the key role of GLP-1 signaling in the effect
of GPBAR1 activation on L-cell differentiation, we tested
other efficient L-cell secretagogues: a synthetic agonist of
free fatty receptor 1 (FFAR1 or GPR40), AM-1638, and
a lipid amide receptor GPR119 agonist, AR53. These two
secretagogues were tested alone or in combination with
Figure 2—In-feed L3740 treatment increases oral glucose tolerance, GLP-1 secretion, and L-cell number inmice.A: Blood glucose excursion during
anoral glucose tolerance test after L3740 treatment (n510 for eachseries).B: Areaunder thecurve (AUC) fromdata inpanelA. Ctrl, control.C: Plasma
GLP-1 concentrations in control and L3740-treatedmice before the test and 10min after glucose gavage (n5 8 for each series).D: L-cell percentage
in mouse ileum sections (n5 4 for each series). E: L cells (Gcg-YFP, green) in the ileum of control and L3740-treated mice. Nuclei labeled by DAPI
(blue). Scale bars, 50 mm. F: Expression of Gcg and Ngn3 in mouse ileal epithelium (n 5 4 for each series). *P , 0.05, **P , 0.01, ***P , 0.001.
diabetes.diabetesjournals.org Lund and Associates 619
the 5-HTR4 antagonist. Both agents alone robustly in-
creased the number of L cells in organoids to a similar
degree as L3740 (Fig. 4I), while inhibiting 5-HTR4 abol-
ished the effect of both the FFAR1 agonist and the
GPR119 agonist (Fig. 4I). Thus, these findings in-
dicate that serotonin signaling acts downstream of GLP-1R
signaling, enabling regulation of intestinal cell differenti-
ation into L cells.
DISCUSSION
Based on studies on secondary bile acids produced by
intestinal microbiota, we here propose a general mech-
anism through which GLP-1 secretagogues stimulate L-cell
differentiation and thereby increase L-cell number in the
intestinal epithelium. This mechanism involves paracrine
GLP-1 stimulation of serotonin secretion and downstream
activation of serotonin receptors conceivably on progenitor
cells in the intestinal crypts (Supplementary Fig. 3). Acti-
vation of GPBAR1 increased L-cell differentiation in human
and mouse intestinal organoids, supported by increased
expression of transcription factors guiding L-cell differ-
entiation. Interestingly, the GPBAR1 agonist L3740 only
increased the expression of Gcg and Cck (which is known
to be produced by L-cells to some degree), but not PYY
and Nts, which are expressed in certain populations of L
cells, and these results may reflect the prolonged matu-
ration time for these populations (17). As a large fraction
of enteroendocrine cell subsets express Gcg (29), GPBAR1
activation can further stimulate Gcg expression and pro-
hormone convertase 1/3 (30), thereby converting more
cells into GLP-1–producing cells. Thus, GBPAR1 modu-
lates L-cell differentiation selectively in contrast to earlier
methods to increase the number of L cells (1–3). Using
GPBAR1-deficient mouse organoids, we demonstrate that
the effect indeed was specific for GPBAR1 when L3740
was applied. However, other efficient GLP-1 secretagogues
acting on FFAR1 (GPR40) and GPR119 mimicked the
effect of L3740 on the L-cell number. This is likely due to
high enrichment of GPBAR1, FFAR1, and GPR119 (20) in
L cells and the ability of L cells to secrete large amounts of
GLP-1 upon its Gs activation. Previously, similar effects
on L-cell abundance have been shown for FFAR2 and
FFAR3, receptors for other microbial metabolites, SCFAs
(10).
GLP-1R has been implicated in cell proliferation and
differentiation (31). As data from GLP1R-deficient mice
indicate, GLP-1R signaling specifically regulates L-cell dif-
ferentiation. GLP-1R is mainly expressed within intestinal
intraepithelial lymphocytes, enteric neurons, and entero-
chromaffin cells in the intestinal epithelium, and GLP-1
stimulates release of serotonin (19). The role of serotonin
in growth and maturation of intestine has previously been
described, although these effects were attributed to the
interaction of enterochromaffin cells with enteric neurons
(32,33). Here we show that 5-HTR4 is predominantly
expressed in the crypt in stem cells, supporting earlier
data (34), but also in secretory and endocrine progenitor
cells. Importantly, the serotonin receptor antagonist
abolished the increase in L-cell number induced by GLP-
1 secretagogues. In agreement, activation of serotonin
signaling increased L-cell number regardless of the pres-
ence of GPBAR1 and GLP-1R, indicating that serotonin
acts downstream of GLP-1.
The GPBAR1 agonist L3740 stimulated formation of
new endocrine-committed intestinal cells in vivo in mice.
The increased glucose tolerance and GLP-1 levels in L3740-
treated mice indicates that the increase in L-cell abundance
was physiologically significant. It is possible that positive
influence of bile acids on energy expenditure and improved
glucose metabolism (35) are partially caused by increased
L-cell numbers. Together with our data from human
organoids, this suggests that GPBAR1 may be a potential
therapeutic target for increased endogenous GLP-1 pro-
duction in humans with type 2 diabetes. The current
limitation of use of GPBAR1 agonists as antidiabetic
agents is gall bladder dysfunction (18,36). However, altering
the intestinal microbiota in favor of microorganisms pro-
ducing bile acids (37–39) to activate GPBAR1 locally appears
to be an intriguing possibility.
In conclusion, bile acids may act as regulators of L-cell
number in the intestinal epithelium. Here we show a specific
Figure 3—GPBAR1 stimulation increases L-cell abundance in hu-
man organoids.A: L-cell numbers in control (Ctrl; n5 66) and L3740-
treated human small intestine organoids (n5 44). B: Representative
images of control and L3740-treated human organoids. L cells are
labeled by GLP-1 immunostaining (white arrows), and nuclei are
labeled by DAPI. Scale bars, 50 mm. C: A shift in the organoid
distribution by the cell number after treatment with L3740. Percen-
tages of organoids with various L-cell numbers are presented from
data in panel A. P , 0.05 by x2 contingency test. D: Expression of
NGN3, NEUROD1 (ND1), and GCG (n5 4 for each series, generated
from two human organoid lines). *P , 0.05, **P , 0.01.
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target, GPBAR1, which increases the differentiation into
L cells but does not alter other cell ratios in intestinal
epithelium. We propose a model whereby GLP-1 levels
contribute to control of L-cell abundance through seroto-
nin signaling, explaining the ability of the body to adjust
the L-cell numbers to compensate for changes in nutrient
availability. Finally, our study demonstrates that directing
the differentiation in the intestinal epithelium into spe-
cific cell types is possible and that GPBAR1 (and possibly
other G-protein–coupled receptors) could be a target for
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modulation of L-cell number as a therapeutic strategy
against type 2 diabetes.
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